Cargando…

The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells

The USFDA approved “epigenetic drug”, Decitabine, exerts its effect by hypomethylating DNA, demonstrating the pivotal role aberrant genome-wide DNA methylation patterns play in cancer ontology. Using sensitive technologies in a cellular model of Acute Myeloid Leukemia, we demonstrate that while Deci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chowdhury, Basudev, McGovern, Andrew, Cui, Yi, Choudhury, Samrat Roy, Cho, Il-Hoon, Cooper, Bruce, Chevassut, Timothy, Lossie, Amy C., Irudayaraj, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894448/ https://www.ncbi.nlm.nih.gov/pubmed/25901663 http://dx.doi.org/10.1038/srep09281

Ejemplares similares

Technical advances in global DNA methylation analysis in human cancers
por: Chowdhury, Basudev, et al.
Publicado: (2017)

Notch signaling genes: Myogenic DNA hypomethylation and 5-hydroxymethylcytosine
por: Terragni, Jolyon, et al.
Publicado: (2014)

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
por: Jiang, Xuejie, et al.
Publicado: (2015)

A Study of Alterations in DNA Epigenetic Modifications (5mC and 5hmC) and Gene Expression Influenced by Simulated Microgravity in Human Lymphoblastoid Cells
por: Chowdhury, Basudev, et al.
Publicado: (2016)

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
por: Provez, Lien, et al.
Publicado: (2023)

Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine
por: Li, Hongjiao, et al.
Publicado: (2020)

Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
por: Liu, Zhongfa, et al.
Publicado: (2007)

Expression profiling of DNA methyl transferase I (DNMT1) and efficacy of a DNA-hypomethylating agent (decitabine) in combination with chemotherapy in osteosarcoma
por: Chaiyawat, Parunya, et al.
Publicado: (2020)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter
por: Choudhury, Samrat Roy, et al.
Publicado: (2016)

Epigenetic Editing of Ascl1 Gene in Neural Stem Cells by Optogenetics
por: Lo, Chiao-Ling, et al.
Publicado: (2017)

Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma
por: Choudhury, Samrat Roy, et al.
Publicado: (2015)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
por: Li, Limin, et al.
Publicado: (2018)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine
por: Shao, Jianming, et al.
Publicado: (2023)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
por: Park, Sungwoo, et al.
Publicado: (2023)

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
por: Shao, Jianming, et al.
Publicado: (2022)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells
por: Li, Lanzhu, et al.
Publicado: (2021)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
por: Duchmann, Matthieu, et al.
Publicado: (2018)

Ongoing Clonal Evolution in Chronic Myelomonocytic Leukemia on Hypomethylating Agents: A Computational Perspective
por: Than, Hein, et al.
Publicado: (2018)

Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
por: Carraway, Hetty E., et al.
Publicado: (2020)

Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection
por: Caiado, Francisco, et al.
Publicado: (2019)

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2avuo092r4njdjjn1ck0f46q58